Finance

Lists
Q3 2026 earnings • released • EPS beat +11.45% • Revenue beat +3.01%
See results
AMGN34:BVMF
Amgen Inc. BDR
R$ 88.18
-2.99%
(-2.72) 1D
11-р сарын 6, 11:30:00 (GMT-3)  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN34...
Open
R$ 89.01
High
R$ 89.01
Low
R$ 88.18
Mkt. cap
249.83Т
Avg. vol.
310.00
Volume
7.00
52-wk high
R$ 94.72
52-wk low
R$ 47.76
Shares outstanding
540.91 сая
No. of employees
32 мян
Open
R$ 89.01
High
R$ 89.01
Low
R$ 88.18
Mkt. cap
249.83Т
Avg. vol.
310.00
Volume
7.00
52-wk high
R$ 94.72
52-wk low
R$ 47.76
Shares outstanding
540.91 сая
No. of employees
32 мян
News stories
From web sources and news partners
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc. BDR
CEORobert A. Bradway
Employees31.5 мян
Founded1980
HeadquartersТаузенд Өүкс, Калифорни, Америкийн Нэгдсэн Улс
SectorHealth Care
Industry-
Websiteamgen.com
Last report
2026 оны 11-р сарын 3
Fiscal period
Q3 2026
$ 6.45 / $ 5.79
+11.45%beat
Revenue / Est. (USD)
10.36 тэрбум / 10.06 тэрбум
+3.01%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
2026 оны 9-р сар
Revenue
9.87 тэрбум
8.62 тэрбум
10.05 тэрбум
10.36 тэрбум
Cost of goods sold
2.68 тэрбум
2.50 тэрбум
2.75 тэрбум
1.91 тэрбум
Cost of revenue
2.68 тэрбум
2.50 тэрбум
2.75 тэрбум
1.91 тэрбум
Research and development expenses
2.14 тэрбум
1.72 тэрбум
1.87 тэрбум
2.10 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.95 тэрбум
1.60 тэрбум
1.74 тэрбум
1.68 тэрбум
Operating expense
4.18 тэрбум
3.21 тэрбум
3.73 тэрбум
3.79 тэрбум
Total operating expenses
6.85 тэрбум
5.70 тэрбум
6.48 тэрбум
5.70 тэрбум
Operating income
3.01 тэрбум
2.91 тэрбум
3.57 тэрбум
4.67 тэрбум
Other non operating income
143.00 сая
192.00 сая
145.00 сая
164.00 сая
EBT including unusual items
1.51 тэрбум
2.08 тэрбум
2.77 тэрбум
4.69 тэрбум
EBT excluding unusual items
2.51 тэрбум
2.37 тэрбум
3.06 тэрбум
4.18 тэрбум
Income tax expense
181.00 сая
265.00 сая
393.00 сая
822.00 сая
Effective tax rate
11.96%
12.72%
14.20%
17.54%
Other operating expenses
82.00 сая
-113.00 сая
116.00 сая
10.00 сая
Net income
1.33 тэрбум
1.82 тэрбум
2.38 тэрбум
3.86 тэрбум
Net profit margin
13.51%
21.11%
23.62%
37.28%
Earnings per share
5.29
5.15
6.29
6.45
Interest and investment income
408.00 сая
-
-
-
Interest expense
-1.06 тэрбум
-657.00 сая
-673.00 сая
-653.00 сая
Net interest expenses
-653.00 сая
-657.00 сая
-673.00 сая
-653.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
4.02 тэрбум
4.03 тэрбум
4.69 тэрбум
5.79 тэрбум
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google аппс